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Cell-based immunotherapy strategies target tumors directly (via cytolytic effector cells) or
aim at mobilizing endogenous anti-tumor immunity. The latter approach includes dendritic
cells (DC) most frequently in the form of in vitro cultured peripheral blood monocytes-
derived DC. Human blood γδT cells are selective for a single class of non-peptide agonists
(“phosphoantigens”) and develop into potent antigen-presenting cells (APC), termed γδT-
APC within 1–3 days of in vitro culture. Availability of large numbers of γδT-APC would be
advantageous for use as a novel cellular vaccine. We here report optimal γδT cell expan-
sion (>107 cells/ml blood) when peripheral blood mononuclear cells (PBMC) from healthy
individuals and melanoma patients were stimulated with zoledronate and then cultured
for 14 days in the presence of IL-2 and IL-15, yielding γδT cell cultures of variable purity
(77± 21 and 56±26%, respectively). They resembled effector memory αβT (TEM) cells
and retained full functionality as assessed by in vitro tumor cell killing as well as secretion
of pro-inflammatory cytokines (IFNγ,TNFα) and cell proliferation in response to stimulation
with phosphoantigens. Importantly, day 14 γδT cells expressed numerous APC-related cell
surface markers and, in agreement, displayed potent in vitro APC functions. Day 14 γδT cells
from PBMC of patients with cancer were equally effective as their counterparts derived
from blood of healthy individuals and triggered potent CD8+ αβT cell responses following
processing and cross-presentation of simple (influenza M1) and complex (tuberculin puri-
fied protein derivative) protein antigens. Of note, and in clear contrast to peripheral blood
γδT cells, the ability of day 14 γδT cells to trigger antigen-specific αβT cell responses did not
depend on re-stimulation. We conclude that day 14 γδT cell cultures provide a convenient
source of autologous APC for use in immunotherapy of patients with various cancers.
Keywords: γδT cells, antigen-presentation, vaccine, αβT cells
INTRODUCTION
Dendritic cells (DC) are master regulators of adaptive immunity
and are long thought to be a prime target for the treatment of
various diseases, including chronic infections, autoimmune dis-
eases, and cancer (1, 2). In principle, DC-based immunotherapies
involve two separate strategies: infusion of patients with in vitro
generated, vaccine-loaded DC and injection of patients with bio-
logicals targeting the patients’ own DC (3). The former approach
has the advantage of modifying in vitro cultured DC prior to their
use as cellular vaccine. However, DC do not grow during in vitro
culture and are scarce in peripheral blood. Therefore, a common
strategy involves the in vitro generation of DC by culturing blood-
derived monocytes for 6 days in the presence of IL-4 and GM-CSF
[monocyte-derived DC (moDC)] (4). Again, this method does
not yield unlimited numbers of moDC as the majority of cells die
during the in vitro differentiation process. A hallmark of DC is
their exquisite functional diversity underscored by the numerous
distinct DC subsets present in blood and peripheral tissue and
their varied reactivity to maturation factors, including cytokines
and microbial stimuli (5). These multiple factors may have limited
the use of DC-based cellular vaccines in the clinic, explaining the
paucity in approved cell products [except for Sipuleucel-T (6)],
despite decades of fundamental and clinical research (3).
γδT-antigen-presenting cells (APC), activated γδT cells with
antigen-presentation function, might be a valuable alternative to
moDC for use as cellular vaccines in the treatment of patients
with cancer (7). γδT-APC are generated during short-term acti-
vation of human peripheral blood γδT cells expressing Vγ9Vδ2-
TCR. This particular γδT cell subset predominates in peripheral
blood (1–5% of total T cells) and recognizes a class of non-
peptide ligands, so-called “phosphoantigens.” The most potent
phosphoantigen, (E)-4-hydroxy-3-methyl-but-2-enyl pyrophos-
phate (HMBPP), is of microbial origin and outperforms the struc-
turally related phosphoantigen found also in higher organisms,
www.frontiersin.org July 2014 | Volume 5 | Article 344 | 1
Khan et al. Human γδT cell-based vaccine
isopentenyl pyrophosphate (IPP), by >103-fold (8). Recent evi-
dence underscores the importance of butyrophilin 3A1/CD277 in
presenting HMBPP or IPP to Vγ9Vδ2-TCR+ γδT cells, and dif-
ferences in binding kinetics may explain the striking difference
in their potency to induce cell responses (9, 10). Activation of
Vγ9Vδ2-TCR+ γδT cells by HMBPP/IPP or aminobisphospho-
nates (nBP) that increase intracellular IPP levels due to inhibition
of IPP-metabolizing enzymes, leads to multiple cell responses,
including cytokine and chemokine secretion as well as tumor cell
lysis (11–13). Indeed, the broad range of tumor cells that are being
killed during in vitro culture with Vγ9Vδ2-TCR+ γδT cells (abbre-
viated hereafter as γδT cells) provided the rationale for targeting
these cells in current cancer immunotherapy trials (14, 15).
We here propose to explore the DC-like APC properties of
γδT cells and to discuss the possibility of translating our findings
into a novel type of cellular vaccine. The principles underlying
the two γδT cell-based translational approaches, i.e., tumor cell-
killing and αβT cell activation, differ fundamentally from each
other. Most notably, tumor cell-killing requires that infused γδT
cells reach the sites of tumors in order to kill tumor cells during
cell-to-cell contact. By contrast, the APC properties of γδT cells
target endogenous αβT cells and, in order to do so, tumor-antigen-
presenting γδT cells need to interact with tumor-specific αβT cells
within secondary lymphoid tissues (spleen, lymph nodes). We do
not anticipate that the mobilization of tumor-specific αβT cells in
spleen and lymph nodes is hindered by those γδT cells that home
to the tumor tissue. In fact, it may well be that tumor cell-killing
by itself leads to in situ prepared tumor-antigen-presenting γδT
cells that may further enhance endogenous αβT cell responses.
What is the evidence for DC-like properties of activated γδT
cells? Similar to tumor cell-killing, the APC functionality is the
result of extensive in vitro studies facilitated by the fact that human
peripheral blood γδT cells uniformly respond to HMBPP/IPP.
Resting peripheral blood γδT cells express receptors for inflamma-
tory chemokines and, similar to TEM cells, are in pole position to be
recruited to sites of inflammation (16–19). However, during short-
term (1–2 days) activation with IPP, the inflammatory homing
program inγδT cells is switched to a transient lymph node-homing
program characterized by CCR7 expression, suggesting their con-
tribution to lymph node activities (16). In addition to cytokine
production, IPP stimulation results in surface expression of mul-
tiple receptors commonly associated with DC, including antigen-
presentation molecules (MHC class II), co-stimulatory receptors
(CD40, CD80, CD86), maturation markers (CD83), and adhe-
sion receptors (CD11a, CD11b, CD11c, CD18, CD50, CD54) (20).
Indeed, activated γδT cells are efficient antigen-processing and
peptide–MHC-presenting cells shown to trigger primary (naïve)
and memory responses in both CD4+ and CD8+ αβT cells (20).
Activated γδT cells even trigger antibody production in B cells that
may be facilitated by additional co-stimulatory molecules (ICOS,
OX40, CD70) (16, 21). Relevant to tumor cell-killing by cytotoxic
T cells, activated γδT cells are also able to trigger CD8+ αβT cells
via antigen cross-presentation, a process involving the uptake and
proteasomal processing of exogenous antigen and peptide load-
ing onto intracellular MHC class I molecules (22, 23). Several
laboratories have confirmed and extended these initial observa-
tions (24–28), corroborating the DC-like properties of short-term
activated γδT cells, abbreviated as γδT-APC.
An obvious advantage over DC-based vaccines is the capacity
of peripheral blood γδT cells to selectively expand to large num-
bers during in vitro culture in response to HMBPP/IPP or nBP. In
fact, numerous studies have already demonstrated that large num-
bers (109 cells) of γδT cells can be grown from peripheral blood
mononuclear cells (PBMC) of patients with cancer, although the
level of expansion was shown to be influenced by disease stage
and/or γδT cell frequency (29–40). Here, we report that expanded
γδT cells maintain critical features of γδT-APC, including DC-
like antigen-presenting and co-stimulatory molecules as well as
the ability to induce antigen-specific CD4+ and CD8+ αβT cell
responses. A protocol for the preparation of a γδT-APC-based
autologous tumor vaccine is discussed.
MATERIALS AND METHODS
MEDIA, REAGENTS, AND ANTIBODIES
The tissue culture medium used throughout was RPMI 1640 sup-
plemented with 2 mM l-glutamine, 1% non-essential amino acids,
1% sodium pyruvate, 50µg/ml penicillin/streptomycin (GIBCO
Life Technologies, Carlsbad, CA, USA), and combination of 5%
FCS (Hyclone Laboratories, Logan, UT, USA) with 5% human
serum (prepared in-house). Human recombinant IL-2 (Proleukin)
and IL-15 were purchased from Novartis (Basel, Switzerland)
and Miltenyi Biotec (Bergisch Gladbach, Germany), respectively.
MicroBeads conjugated to mouse monoclonal anti-PE antibod-
ies (Miltenyi Biotec) were used for magnetic cell separation.
Mouse monoclonal antibodies (mAbs) specific for CD3 (UCHT1,
SK7XX), CD4 (RPA-T4), CD8 (SK1, HIT8a, RPA-T8), CD11a
(HI-111), CD14 (M5E2), CD25 (M-A251), CD27 (M-T271),
CD45RA (HI100), CD45RO (UCHL-1), CD54 (HA58), CD56
(B159), CD57 (NK-1), CD62L (DREG-56), CD69 (FN50), HLA-
DR (L243), CCR7 (3D12), Vδ2-TCR (B6.1), and IFNγ (β27) were
from BD Biosciences (San Jose, CA, USA); mouse mAbs specific
for TCR-Vγ9 (Immu360) and CD40 (mAB89) were from Beckman
Coulter (Brea, CA, USA); mouse mAbs specific for CD28 (28.2),
CD86 (IT2.2), CD127 (A019D5), and HLA-ABC (w6/32) were
from Biolegend (San Diego, CA, USA); mouse mAb specific for
CD19 (SJ25C1), CD25 (BC96), CD80 (2D10.4), NKG2D/CD314
(1D11), and PE-Cy7 conjugated streptavidin were from eBio-
science (San Diego, CA, USA); mouse mAb anti TCR-Vγ9 (7A5)
was from Thermo Scientific (Waltham, MA, USA); mouse IgG1
mAb (NCG01) was from Abcam (Cambridge, UK); mouse mAb
specific for HLA-A2 (BB7.2) was from Serotec (Kidlington, UK).
In addition, rat mAb specific for CCR7 (3D12) was from M. Lipp
(Max Delbruck Center for Molecular Medicine, Berlin, Germany),
and mouse mAb anti-CD18 (TS1-18) was from R. Pardi (Institute
San Raffaele, Milano, Italy), and were used together with appro-
priate isotype controls during flow cytometric analyses. Biotin-
SP-conjugated donkey anti-rat IgG was from Jackson ImmunoRe-
search Laboratories (West Grove, PA, USA). Carboxyfluorescein
diacetate succinimidyl ester (CFSE), LIVE/DEAD® Fixable Aqua
Dead Cell Stain Kit and Accucheck counting beads were from
Invitrogen-Life Technologies (Carlsbad, CA, USA). CellVue and
PKH26 were from Sigma-Aldrich (St. Louis, MO, USA).
Peptides were purchased from Severn Biotech (Kidderminster,
UK). Recombinant influenza PR8 M1 protein was generated in
E. coli, isolated to >95% following standard chromatographic
procedures and stored in aliquots at−80°C.
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BLOOD DONORS
Donors comprised healthy donors and patients with advanced
melanoma in the UK and patients with diverse advanced can-
cers in Italy. The study with venous blood from healthy human
individuals was approved by the South East Wales Ethics Commit-
tee under reference number 08/WSE04/17. Samples from patients
with melanoma, along with anonymized demographic and treat-
ment data, were acquired from the Human Biomaterials Resource
Centre (HBRC), University of Birmingham. The HBRC is a
biorepository licensed by the Human Tissue Authority, UK and
samples were taken with prospective written generic consent for
research use. Samples of hematologic malignancies and metasta-
tic colon cancer were obtained from patients enrolled in trials of
translational and experimental medicine at Humanitas Research
Hospital, Milan, Italy. These protocols have been approved by the
Institutional Review Board (IRB) of the same institute (Approvals
1009 for hematologic malignancies and 1021 for metastatic colon
cancer), and each patient had signed a consent form that has been
approved by the IRB.
IN VITRO EXPANSION OF γδT CELLS
Whole blood samples from healthy donors and patients with can-
cer were taken into heparin/EDTA. PBMCs were isolated by Ficoll
(Lymphoprep, Axis-Shield, Dundee, UK) gradient centrifugation
from whole blood and frozen in liquid nitrogen until use. In
order to deplete Treg cells, CD25+ cells in PBMC were stained
with PE-conjugated anti-CD25 mAb in combination with anti-
PE microbeads and then retained on magnetic columns accord-
ing to the manufacturer’s instructions (Miltenyi Biotec). The
pass-through was evaluated for CD25+ cell depletion by flow
cytometry and designated as CD25+ cell depleted PBMC prepa-
rations. For in vitro γδT cell expansion, PBMC or CD25+ cell
depleted PBMC were stimulated with 1µM zoledronate (Zometa;
Novartis, Basel, Switzerland) complete RPMI 1640 medium at
a density of 106 cells/ml in 24-well plates and cultured at 37°C
in 5% CO2. At day 5, 8, and 11, cell cultures were split in
fresh medium and supplemented with 100 IU/ml IL-2 alone or
with 100 IU/ml IL-2 and 20 ng/ml IL-15. At day 14, γδT cell
cultures were examined by flow cytometry for γδT cell expan-
sion, purity, and viability as well as expression of cell surface
markers.
CYTOKINE PRODUCTION
Day 14 expanded γδT cells from PBMC of healthy individuals
and melanoma patients were stimulated with 10 nM HMBPP
at 1× 106 cells/well in complete RPMI 1640 medium and cul-
tured for 48 h. Cytokines and chemokines in cell-free culture
medium were determined using ELISA kits for IL-1β, IL-8,
CCL-1, CCL-4, CXCL13 (R&D Systems, Minneapolis, MN, USA)
and IFNγ, TNFα, IL-10, IL-17A, TGFβ1, CCL-2 (eBioscience)
and a Dynex MRX II reader (DYNEX Technologies, Chantilly,
VA, USA).
CYTOTOXICITY ASSAY
Day 14γδT cell tumor cell-killing activity was tested on the chronic
myeloid leukemia cell line KBM7 that was maintained in (1×)
Iscove’s Modified Dulbecco’s Medium (GIBCO Life Technologies,
Carlsbad, CA, USA) supplemented with 10% fetal calf serum and
penicillin/streptomycin. KBM7 cells were labeled with the mem-
brane dye CellVue prior to co-culture with γδT cells. Alternatively,
in order to determine the effect of sensitization of KBM7 cells
with HMBPP on tumor cell-killing, KBM7 cells were cultured for
18 h in the presence of 1µM HMBPP and then labeled with the
alternative cell membrane dye PKH26 and mixed with untreated
CellVue labeled KBM7 cells at a 1:1 ratio. CellVue labeled KBM7
cells or a mixture of Pkh26 labeled, HMBPP-treated KBM7 cells
and untreated CellVue labeled KBM7 cells were then incubated
together with day 14 γδT cells at increasing effector/target cell
ratios for 6 h at 37°C, 5% CO2. KBM7 cell-killing was determined
by flow cytometry by gating on CellVue+ and Aqua+ cells or
PKH26+ and Aqua+ cells; Accucheck counting beads were also
used for dead cell count.
In order to examine the involvement of γδT cell receptors in
KBM7 cell-killing, day 14 γδT cells pre-treated with antibodies
to Vγ9-TCR (10µg/ml), to Vδ2-TCR (1:100 and 1:200 dilution),
to CD18 (10µg/ml), and to NKG2D (10µg/ml) or control mAb
(10µg/ml) before co-culture with KBM7 cells.
ANTIGEN-PRESENTATION ASSAY
Intracellular IFNγ assay
Day 14 γδT cells from HLA-A2+ blood donors were incubated for
16–24 h in the presence of 0.01–1µM influenza M1 protein and
then washed and incubated with brefeldin-A pre-treated, HLA-
A2+ restricted, M1 p58–66-specific CD8+ αβT (CD8+ responder)
cells in 96-well round bottom plates at a ratio of 1:1 (1–0.5× 106
cells/well) as described (23). Alternatively, day 14 γδT cells were
pulsed with 0.1µM M1 p58–66 and then rigorously washed
before use as APC. After 5–6 h, cells were stained with antibod-
ies to CD3, Vγ9-TCR, and CD8, fixed, and then permeabilized in
order to detect intracellular IFNγ by flow cytometry. Brefeldin-A
treated CD8+ responder cells cultured alone or in the presence
of PMA and ionomycin served as negative and positive control,
respectively (22, 23).
Proliferation assays
Day 14 γδT cells from HLA-A2+ blood donors were treated
with influenza M1 protein or pulsed with M1 p58–66 exactly as
described in the intracellular IFNγ assay. Proliferation was mea-
sured in M1 p58–66-specific CD8+ αβT cells present in freshly
prepared, autologous PBMC. Instead of preparing CD3+ or CD8+
αβT cells for use as responder cells (22, 23), PBMC were directly
labeled with 1µM CFSE for 5 min at room temperature and
then washed before use as responder cells. Influenza M1 antigen-
treated γδT cells and CFSE-labeled PBMC were mixed at a ratio
of 1:5 in 96-well round bottom plates. After 6, 8, and 10 days
of culture at 37°C, 5% CO2, responder cells were identified by
staining with antibodies to CD3, CD8 in combination with M1
p58–66-tetramers; CFSElow, M1 p58–66-tetramer+ cells were enu-
merated by flow cytometry. CFSE-labeled PBMC cultured alone
or in the presence of day 14 γδT cells that were not pre-treated
with influenza M1 antigens served as negative controls. In a sec-
ond proliferation assay, day 14 γδT cells were treated with 0.01–
10µg/ml Mycobacterium tuberculosis purified protein derivative
(PPD) before co-culture with autologous, CFSE-labeled PBMC as
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described for influenza M1 protein. Proliferating (CFSElow) cells
were detected after day 6, 8, and 10 of culture by staining for acti-
vated (CD25+) CD3+ T cells in combination with either CD4 or
CD8 and enumerated by flow cytometry.
STATISTICAL ANALYSIS
Statistical analysis was performed using Student’s t -test and results
were considered significant at P-values of <0.05.
RESULTS
OPTIMIZED γδT CELL EXPANSION DURING IN VITRO CULTURE
Previous γδT cell expansion studies commonly used IL-2 as T
cell growth factor in combination with phosphoantigen or nBP
as Vγ9Vδ2-TCR+ γδT cell-specific stimuli (29–40). In over 10
individual experiments, we have noticed substantial variations in
the yield of γδT cells following the stimulation of PBMC from
healthy individuals with zoledronate and their subsequent cul-
ture for 14 days in the presence of IL-2. The ability of γδT cells
to expand to large numbers is an important aspect in consider-
ing their use in immunotherapy and represents a clear advantage
over moDC that fail to grow during tissue culture. Therefore, we
sought to optimize the culture conditions for reliable expansion
of γδT cells by culturing zoledronate-stimulated PBMC from both
healthy individuals and patients with cancer in the presence of IL-
2 plus IL-15. In addition, due to their inhibitory properties, we
examined the effect of removing Treg cells from PBMC on γδT
cell proliferation during subsequent tissue culture. Accordingly,
cultures were initiated by addition of zoledronate to PBMC either
with or without prior depletion of CD25+ cells. After 5 days, IL-2
alone or in combination with IL-15 was added and cultures were
maintained until day 14 when cells were harvested and analyzed
for cell survival, γδT cell content, and purity. As summarized in
Table 1, we demonstrate that the combination of IL-2 and IL-15 is
approximately 10-fold better than IL-2 alone, yielding >20× 106
γδT cells per 106 input PBMC in 8 out of 13 γδT cell cultures
reaching >70% purity. Of note, consistently higher cell viability
was obtained in combination with IL-15 compared to IL-2 alone.
Depletion of Treg cells (or CD4+ and CD8+ T cell subsets; not
shown) in input PBMC preparations did not significantly improve
the outcome of the IL-2 or IL-2/IL-15 cultures, both in terms of
γδT cell purity and cell viability. In our hands, addition of IL-2
right from the start frequently led to substantial αβT cell growth
and reduced γδT cell counts in day 14 cultures, which was pre-
vented by delayed (day 5) IL-2 addition (alone or in combination
with IL-15).
Next, we tested our γδT cell expansion protocol on PBMC
from patients with cancer (Table 2). Out of 10 PBMC samples
from melanoma patients with advanced disease, one sample with
low γδT cell count (0.06% of PBMC) failed to respond during
in vitro culture. However, the PBMC samples from the remain-
ing nine patients responded well to zoledronate plus IL-2/IL-15
with a range of expansion factors that did not differ substan-
tially from PBMC of healthy donors (Table 3). This finding was
somewhat surprising considering the substantial variation in the
cellular composition of PBMC from melanoma patients as com-
pared to healthy individuals (Figure 1). For instance, the fraction
of CD3+ T cells, and most notably CD8+ T cells, was consistently
lower in PBMC from melanoma patients, whereas the opposite was
found for CD14+ monocytes. Similarly, the Vγ9+ γδT cell count
in PBMC from melanoma patients was approximately twofold
lower than in PBMC from healthy individuals, which may have
been related to the age gap between healthy and melanoma blood
donors (41). ReducedγδT cell numbers in the original PBMC sam-
ples may have accounted for the twofold lower yields of γδT cells at
day 14 of culture (Tables 1 and 3). Of interest, and in clear contrast
to a recent report (35), initial depletion of Treg cells in PBMC did
not further improve the outcome of γδT cell cultures; quite the
contrary, the expansion fold and total yield of γδT cells was sub-
stantially and consistently reduced following removal of CD25+
cells, which was not observed in control experiments with PBMC
from healthy individuals (Figure 2). We have not further examined
this observation but suspect that removal of CD25+ cells may have
Table 1 | In vitro expansion of Vγ9Vδ2-TCR+ γδT cells from PBMC of healthy donors in response to zoledronate.
Treatment PBMC CD25+ depleted
IL-2 IL-2/IL-15 IL-2 IL-2/IL-15
Donors 6 13 6 12
Input of Vγ9+ T cells (×106/106 PBMC)a 0.019±0.010 0.021±0.011 0.019±0.010 0.022±0.012
DAY 14 CULTURES
Live cells (%)b 71±11 85±11 77±9 87±6
CD3+ cells (%)c 92±10 96±3 94±4 95±4
Vγ9+ T cells (%)c 56±27 77±21 62±22 74±18
Yield of Vγ9+ T cells (×106/106 PBMC)d 2±1.2 29±10.4 2.9±0.94 23±8.7
Expansion folde 104±120 1370±949 150±94 1025±721
aInitiation of cultures at 10 6 PBMC per well (24-well plate).
bLive cells defined as Aqua− cells.
cPercentage of total live (Aqua−) cells.
dNumber of Vγ9+ T cells per 106 of input PBMC after 14 days of culture.
eYield of Vγ9+ T cells divided by input Vγ9+ T cells.
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Disease Surgery and radiotherapy Therapy
1 68 F 2008 Lymph nodes and lung metastases Regional nodal dissection None
2 65 M 2011 Lung and brain metastases Regional nodal dissection None
3 49 M 2012 No current known metastases Regional nodal dissection; excision
distant cutaneous and brain
metastases; whole brain radiotherapy
None
4 74 F 2010 Nodal, lung, and brain metastases Regional nodal dissection None
5 60 F 2011 Nodal and liver metastases Regional nodal dissection None
6 52 F 2011 Distant skin metastases Regional nodal dissection None
7 31 F 2007 Skin and lung metastases Regional nodal dissection None
8 33 F 2001 Lung metastases Regional nodal dissection; excision
gastro-intestinal metastases
None
9 33 M 2010 Skin, lung, and bone metastases Regional nodal dissection Dexame-thasone
10 83 M 2012 Nodal, lung, and liver metastases Regional nodal dissection Imatinib
F, female; M, male.
Table 3 | In vitro expansion of Vγ9Vδ2-TCR+ T cells from PBMC of
melanoma patients in response to zoledronate.
Treatment of PBMC IL-2/IL-15 CD25+ depleted
IL-2/IL-15
Donors 9 9
Input of Vγ9+ T cells (x106/106 PBMC)a 0.0095±0.01 0.0095±0.01
DAY 14 CULTURES
Live cells (%)b 85±7 84±6
CD3+ cells (%)c 95±4 86±15
Vγ9+ T cells (%)c 54±33 56±26
Yield of Vγ9+ T cells (x106/106 PBMC)d 8.2±7.23 2.2±2.72
Expansion folde 861±723 230±272
aInitiation of cultures at 106 PBMC per well (24-well plate).
bLive cells defined as Aqua− cells.
cPercentage of total live (Aqua−) cells.
dNumber of Vγ9+ T cells per 106 of input PBMC after 14 days of culture.
eYield of Vγ9+ T cells divided by input Vγ9+ T cells.
led to a reduction in zoledronate-reactive cells in PBMC samples of
patients with cancer. Finally, we did not notice a significant differ-
ence in γδT cell yield and purity when zoledronate was substituted
with IPP or HMBPP (not shown). Overall, our findings document
that γδT cells in PBMC from melanoma patients responded well to
zoledronate plus IL-2/IL-15. The observed donor-to-donor varia-
tions fit well with a recent study carried out with PBMC from 30
melanoma patients, although in the latter study PBMC cultures
were terminated at day 7 (42).
Day 14 γδT cells from melanoma patients were also similar to
those derived from PBMC of healthy individuals in terms of their
activation and differentiation markers (Figure 3). The degree of
differentiation was determined by correlating cell surface expres-
sion of CD27, CD28, CD45RA, and CD45RO, revealing that all
day 14 γδT cells expanded in IL-2/IL-15 expressed the memory
marker CD45RO. By contrast, expression of CD27 and CD28 was
highly variable in both day 14 γδT cells derived from melanoma
patients (3–19 and 2–76%, respectively; n= 4) and healthy donors
(2–19 and 15–86%, respectively; n= 5), reminiscent of effector
memory (TEM) cells rather than terminally differentiated effector
memory (TEMRA) cells. CD127, a marker for homeostatic pro-
liferation of αβT cells, was not detected. By contrast, killer cell
lectin-like receptor G1 (KLRG1) was present on most expanded
γδT cells (Figure 3). The inhibitory receptors PD-1 and CTLA-4
were not detected on day 14 γδT cells of patients or healthy blood
donors, whereas the exhaustion marker CD57 was present at var-
ious levels (7–64%; n= 8). Finally, the combination of homing
molecules suggests a preference for inflammatory tissues (CXCR3,
CCR4, CCR5, CD11a, CD54, etc.) as opposed to secondary lym-
phoid organs (CXCR5, CCR7, CD62L) (not shown and see below).
We conclude that the addition of IL-2 plus IL-15 to zoledronate-
stimulated PBMC resulted in large numbers of in vitro expanded
γδT cells with a TEM cell-like phenotype while lacking markers
commonly associated with inhibitory T cells.
RESPONSIVENESS OF EXPANDED γδT CELLS TO PHOSPHOANTIGENS
The use of expanded γδT cells in immunotherapy requires a
detailed knowledge about their functionality pertaining to both
APC-related and -unrelated cell responses. In agreement with phe-
notypic marker expression (see above), day 14 γδT cells retained
responsiveness to HMBPP as evidenced by cytokine production
(Table 4), most notably the pro-inflammatory cytokines IFNγ and
TNFα. Secretion of TGFβ and IL-10 was relatively low, yet highly
variable and not affected by HMBPP treatment whereas IL-1β,
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FIGURE 1 | Cellular composition of PBMC from healthy individuals and
melanoma patients. PBMC were analyzed by flow cytometry for the content
of T cells (CD3), T cell subsets (CD8, CD4, Vγ9+ γδT cells (Vγ9)), CD14+
monocytes, CD19+ B cells, and CD3−CD56+ NK cells, expressed as percent
(%) of total live cells in PBMC. Data include PBMC from 10 healthy individuals
(Ctrl) and 9 melanoma patients (Mel).
FIGURE 2 | Negaitve effect of CD25+ cell depletion on expansion of γδT
cells from melanoma patients. PBMC from healthy individuals (n=10)
and melanoma patients (n=9) were depleted (CD25-neg) or not (PBMC) of
Treg cells prior to stimulation with zoledronate plus IL-2/IL-15. Expansion fold
is the ratio between the number of γδT cells in day 14 γδT cultures and the
input γδT cells, i.e., the number of γδT cells present in PBMC at the
beginning of cell culture.
IL-12, and IL-17 were not detected. In addition, the chemokines
CXCL8, CCL1, and CCL4 were found to be present. Again,
cytokine secretion profiles did not differ substantially between
day 14 γδT cells derived from healthy individuals as compared to
melanoma patients. As expected (43), zoledronate alone was inac-
tive and cytokine responses were only seen when zoledronate plus
monocytes were added to day 14 γδT cells (not shown).
Functionality of day 14 γδT cells was also evidenced in their
proliferation responses. In the presence of IL-2 and IL-15 but in
the absence of HMBPP, day 14 γδT cells continued to proliferate at
variable levels (zero to sixfold) during subsequent 7 days cultures,
which may reflect the considerable variation in activation states,
as evidenced by the expression of CD69 [75–86 and 24–96% in
γδT cells from healthy individuals (n= 5) and melanoma patients
(n= 9), respectively] and CD25 [2–36 and 2–76% in γδT cells
from healthy individuals (n= 5) and melanoma patients (n= 9),
respectively]. Addition of HMBPP killed>50% of day 14 γδT cells
within 24 h, but the residual cells resumed proliferation to levels
routinely exceeding the ones seen in cultures without addition of
HMBPP.
We also examined in vitro tumor cell-killing activity by day 14
γδT cells. The underlying mechanisms are still debated but have
been proposed to involve eitherγδTCR- or NK receptors-mediated
processes or a combination of both pathways. We demonstrate
that day 14 expanded γδT cells retained tumor cell-killing activity
without the need for prior activation (Figure 4). However, the tar-
get tumor cells (myeloid KBM7 cells) were much more efficiently
killed following overnight incubation with HMBPP. This effect
was reduced to the level of untreated KBM7 cells when γδTCR-
blocking Abs were included, demonstrating that the HMBPP pre-
treatment of tumor cells directly promoted the γδTCR-mediated
KBM7 killing. γδTCR-blocking Abs did not affect the killing of
untreated KBM7 cells whereas the addition of CD18- or NKG2D-
blocking Abs reduced the killing of both untreated and HMBPP-
pre-treated KBM7 cells (not shown). We conclude that day 14 γδT
cells retained their ability to respond to Vγ9Vδ2-TCR-specific lig-
ands and were able to generate cell responses that were typically
seen with freshly isolated γδT cells.
ANTIGEN-PRESENTATION BY EXPANDED γδT CELLS (γδT-APCs)
The purpose of this study was to determine whether expanded
γδT cells could be potentially used as a novel type of cellular
vaccine for the treatment of patients with cancer. Therefore, we
sought to establish whether day 14 γδT cells, as opposed to short-
term activated γδT cells (20, 22, 23), expressed APC markers and
were able to induce in vitro antigen-specific αβT cell responses.
A hallmark of γδT-APC generated during short-term activation
of peripheral blood γδT cells was their high-level expression
of antigen-presentation (MHC I and II), co-stimulation (CD40,
CD80, CD86, etc.), adhesion (CD11a, CD54, etc.), and lymph node
homing (CD62L, CCR7) molecules (20). Of interest, and in clear
contrast to γδT cells freshly isolated from peripheral blood, day 14
γδT cells retained many of these APC markers, most notably CD80,
CD86, and HLA-DR (MHC II) (Figure 5). The adhesion mol-
ecules CD11a and CD54 were still uniformly expressed whereas
CD40 and CCR7 (not shown) were low or absent. Maintenance
of crucial APC markers may well reflect the presence (albeit at
various levels) of activation (CD69) and/or proliferation (CD25)
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FIGURE 3 | Activation and differentiation marker expression on day 14
γδT cells from melanoma patients and healthy individuals. Day 14 γδT
cells from PBMC of healthy individuals and melanoma patients were
analyzed by flow cytometry for the expression of activation and
differentiation markers by gating on Vγ9+ cells in combination with the cell
surface markers as indicated. One representative example for each of day
14 γδT cell cultures of healthy individuals (n=5) and melanoma patients
(n=4) are shown.
Table 4 | Secretion of cytokines by day 14 γδT cells following stimulation with PA.
Cytokinesc (pg/ml)
Stimulationb IFNγ TNFα TGFβ IL-10
Healthya – 7900±7600 23±24 77±97 129±58
HMBPP 32000±22000 550±427 32±55 95±57
Melanomaa – 2800±1700 20±6 238±172 183±317d
HMBPP 26000±7000 130±64 247±45 205±353d
aDay 14 γδT cells from PBMC of either three healthy individuals or three melanoma patients.
bTreatment of day 14 γδT cells with or without 10 nM HMBPP.
cCytokines determined by ELISA.
dTwo out of three melanoma γδT cell cultures has no (0 pg/ml) IL-10, irrespective of HMBPP treatment.
markers, which were low/absent on resting (day 0) γδT cells. Of
interest, re-stimulation of day 14 γδT cells with HMBPP for 3 days
resulted in moderate CCR7 and CD62L expression (4–16% of
cells), indicating that extensively expanded γδT cells retained in
part the ability to home to secondary lymphoid tissues. Together,
these data demonstrate that day 14 γδT cells retained many APC
markers that are routinely induced in short-term activated γδT
cells and, importantly, that APC marker expression did not differ
between day 14 γδT cells derived from healthy individuals and
melanoma patients. In fact, preliminary data with PBMC from
melanoma-unrelated patients with cancer, including patients with
Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL),
and colorectal carcinoma (CRC), revealed similar APC marker
expression on expanded γδT cells (not shown), indicating that the
APC phenotype is a general characteristic of expanded γδT cells.
Antigen-presenting cell marker expression suggested that day
14 γδT cells would function as APC without the need for re-
stimulation, i.e., treatment with phosphoantigens, which is in clear
contrast to γδT cells freshly isolated from peripheral blood that
required stimulation (20). First, we tested the ability of day 14 γδT
cells to induce αβT cell proliferation in response to M. tuberculo-
sis PPD as carried out previously (20). To mimic the situation
of a first-in-man clinical trial, we used unfractionated PBMC
(as opposed to purified αβT cells) as responder cells. Following
treatment with PPD, day 14 γδT cells were mixed with 5-(and 6-
)carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled,
autologous PBMC and proliferating CD4+ and CD8+ αβT cells
were identified as CD25+ CFSElow cells at d4, d6, and d8 of cul-
ture. The representative example in Figure 6 clearly demonstrates
that day 14 γδT cells were able to process PPD and present PPD-
derived peptides on MHC class I and II to CD8+ and CD4+ αβT
cells, respectively, at PPD concentrations as low as 0.1µg/ml. Fur-
thermore, CD4+ αβT cells proliferated much better than CD8+
αβT cells as evidenced by their higher background (absence of
γδT cells) and maximal responses (γδT cells treated with 10µg/ml
PPD). Although clearly evident, CD8+ αβT cell responses were
smaller, which may reflect the inefficiency of antigen cross-
presentation, a lower frequency of PPD-specific CD8+ memory T
cells among PBMC, lack of endogenous IL-2 production required
for proliferation or a combination of these factors.
In order to examine antigen cross-presentation in more detail,
we incubated day 14 γδT cells with the influenza M1 protein,
which requires proteasomal processing and loading of the M1
immunodominant peptide p58–66 onto intracellular HMC class
I (HLA-A2) molecules (22, 23). Following 24 h incubation with
graded concentrations of M1 protein, day 14γδT cells were washed
and incubated with M1 responder T cells (HLA-A2+, M1p58-66-
specific CD8+ αβT cells). After 6 h, intracellular IFNγ production
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FIGURE 4 | In vitro tumor cell-killing by day 14 γδT cells. (A) Myeloid
leukemia KBM7 target cells were labeled with the cell membrane dye PKH26
and mixed with day 14 γδT cells at target to effector cell ratios as indicated.
After 6 h of incubation at 37°C, remaining live target cells were determined by
including flow cytometry counting beads. Percent (%) killing refers to the ratio
of remaining to input target cells×100. As control (Ctrl), targets cells were
cultured for 6 h in the absence of γδT cells; representative of three
experiments. (B) KBM7 target cells were cultured overnight in the presence
(+HMBPP) or absence (−) of 1µM HMBPP. The two cultures were labeled
with either PKH26 or Cellvue and added to day 14 γδT cells at a target to
effector cell ratio of 1:10. To examine the mechanisms of target cell-killing,
antibodies to γδTCR (anti-Vγ9; 10µg/ml and anti-Vδ2; 1/100 dilution) and
isotype antibody (mouse IgG1; 10µg/ml) were included in the cultures. After
6 h of culture, percent killing was determined as outlined above by gating on
PKH26+ (HMBPP-treated KBM7) and CellVue+ (control KBM7) cells;
representative of two experiments.
FIGURE 5 | Activation and APC marker expression on day 14 γδT
cells. Cell surface markers as indicated were determined by flow
cytometry on (Vγ9+) γδT cells present in freshly isolated PBMC of
healthy individuals (Healthy, day 0) and in day 14 γδT cell cultures
derived from PBMC of healthy individuals (Healthy, day 14) or
melanoma patients (Melanoma, day 14). Representative data of 6
(Healthy, day 0), 5 (Healthy, day 14), and 4 (Melanoma, day 14)
experiments are shown.
in responder cells was measured by flow cytometry (Figure 7A).
Processing of 1 and 0.1µM M1 protein by day 14 γδT cells led
to robust IFNγ responses, similar to what we have published
with short-term activated γδT cells (22, 23). The nine amino
acid M1p58–66 peptide can be pulsed directly (without the need
of prior uptake and intracellular processing) onto cell surface
HLA-A2 on APCs such as DC or, as shown here, γδT cells. Thus,
M1p58–66-pulsed, day 14 HLA-A2+ γδT cells initiated maximal
intracellular IFNγ responses. Day 14 γδT cells from HLA-A2-
individuals were unable to present the M1p58–66 peptide and,
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FIGURE 6 | Proliferation responses to PPD-treated day 14 γδT
cells. Day 14 γδT cells from healthy individuals were treated overnight
with PPD at concentrations as indicated, washed, and mixed with
freshly isolated, CFSE-labeled PBMC from donor-matched blood
samples at a γδT cell to PBMC ratio of 1:5. At day 6 (and days 8 and
10; not shown), proliferating CD4+ and CD8+ αβT cells were identified
by flow cytometry in the Vγ9− CD3+ T cell gate as activated (CD25+)
CFSElow cells. Control cultures (no γδT) contained CFSE-labeled PBMC
but not γδT cells. One representative of four independent
experiments is shown.
thus, served as negative control (not shown). Of note, we did not
detect substantial differences with day 14 γδT cells derived from
either healthy individuals or melanoma patients in their potencies
to induce intracellular IFNγ responses (Figure 7B). Also, donor-
matched monocyte-derive DC from PBMC of healthy individuals
gave similar results, although these experiments were carried out
on separate days (7 days after PBMC isolation; data not shown).
The influenza results were replicated with CMV UL83 peptides
and UL83 p495–503-specific CD8+ αβT responder cells (not
shown). Moreover, day 14 γδT cells from melanoma-unrelated
patients (HL, NHL and CRC; see above) were also capable of
cross-presenting influenza M1 p58–66 to CD8+ αβT responder
cells (not shown). Finally, we investigated the ability of day 14
γδT cells to induce influenza-specific proliferation responses in
primary CD8+ αβT cells (as opposed to cultured cell lines) in
unfractionated PBMC as described above. Data in Figure 7C show
that influenza M1 treated, day 14 γδT cells but not untreated day
14 γδT cells induced robust proliferation responses in p58–66-
specific CD8+ αβT cells. In fact, half of all proliferating (CFSElow)
cells were p58–66-specific whereas these cells did not expand at
all in response to untreated day 14 γδT cells, underscoring the
M1p58–66 specificity of this response. We conclude that day 14
γδT cells behaved similarly to short-term activatedγδT cells (20) in
their ability to process simple (influenza M1) and complex (PPD)
antigens and to induce antigen-specific CD8+ and CD4+ αβT
cell responses. Equally important, day 14 γδT cells from patients
with cancer maintained their APC functionality, suggesting that
patients-derived γδT cells may provide a valuable source for the
generation of an autologous cellular vaccine.
DISCUSSION
The principal aim of the present study was the detailed characteri-
zation of the APC properties of γδT cells following their expansion
during in vitro culture. It is already well known thatVγ9Vδ2-TCR+
γδT cells in PBMC respond vigorously to phosphoantigens or nBP
leading to extremely large numbers during in vitro culture in the
presence of T cell growth factors (29–40). Of note, treatment of
PBMC with phosphoantigen or nBP is highly selective for blood
γδT cells such that unrelated lymphocytes, including αβT cells and
NK cells, do not respond and are “left behind” during in vitro cul-
ture. This simple technique represents a considerable advantage
over αβT cells when large numbers are needed for autologous cell
therapy. Since γδT cells themselves do not produce sufficient IL-
2, this or other T cell growth factors need to be included during
in vitro γδT cell expansion. In our hands, delayed addition of IL-2
prevented early expansion of unrelated lymphocytes and, conse-
quently, prevented outgrowth of αβT cells or NK cells. Since our
previous work with IL-2 provided inconsistent results in terms
of yield and purity of expanded γδT cells, we decided to mod-
ify the in vitro culture procedure by including either IL-15 or
by depleting Treg cells prior to cell culture. In short, Treg cell
depletion, i.e., removal of CD25+ cells by MACS beads isolation
columns, did not affect γδT cell cultures from PBMC of healthy
individuals whereas the addition of IL-15 was clearly beneficial
(see below). Interestingly, we observed that removal of CD25+
cells from PBMC of melanoma patients was inhibitory, support-
ing the view that this treatment removed zoledronate-responsive
cells that were required for optimal γδT cell activation. In fact,
PBMC from patients with cancer contained numerous CD25+
monocytes, which were rare in PBMC from healthy individu-
als, suggesting that their removal might have contributed to the
reduced responsiveness to zoledronate.
IL-2 is known to induce terminal T cell differentiation and,
eventually, activation-induced cell death, which may limit the
expansion and/or viability of cultured T cells (44). By contrast,
and in addition to its T cell growth factor properties, IL-15 induces
T cell survival (45, 46) and, in CD8+ αβT cells, enhances cytotoxic
functions (47, 48). IL-15 alone or in combination with IL-2 has
been used successfully in cultures of tumor-infiltrating αβT cells
isolated from melanoma (49) and Merkel cell carcinoma patients
(50). The action of IL-15 on human blood γδT cells is not well
understood. In agreement with its involvement in homeostatic
proliferation of γδT cells in mice (51, 52), persistence of γδT cells
in patients with cancer has been explained by the presence of
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FIGURE 7 | Influenza M1 cross-presentation to CD8+ αβT cells by day 14
γδT cells. (A) Day 14 γδT cells from HLA-A2+ healthy individuals or melanoma
patients were treated overnight with influenza M1 protein at concentrations
as indicated, washed, and mixed in equal numbers with a HLA-A2-restricted,
p58–66-specific CD8+ αβT cell line. In control experiments, day 14 γδT cells
were directly pulsed with 0.1µM M1 peptide p58–66, washed, and then used
in the APC assay. After 6 h of incubation, intracellular IFNγ production in M1
p58–66-tetramer+ responder cells was determined by flow cytometry.
Responder cells cultured in the absence of stimulation or in the presence of
PMA and ionomycin served as controls for background and maximal IFNγ
responses. (B) Compilation of intracellular IFNγ responses obtained with day
14 γδT cells from PBMC of five HLA-A2+ healthy individuals and four
HLA-A2+ melanoma patients. (C) Day 14 γδT cells from HLA-A2+ healthy
individuals were treated with 1µM M1 protein (M1) or not (No Ag) as
described in (A) and then mixed with donor matched, CFSE-labeled PBMC at
a γδT cell to PBMC ratio of 1:5. Proliferation responses in
p58–66-tereamer+CD8+ αβT cells were determined essentially as described
in Figure 6. One representative of two independent experiments is shown.
endogenous IL-15 (53). Here, we report that the combination of
IL-2 and IL-15 made a substantial difference as compared to IL-2
alone during culturing of γδT cells derived from both patients and
healthy blood donors.
A high yield of expanded, autologous γδT cells is certainly
desirable for their further use as cellular vaccine. However, the
quality of expanded γδT cells in terms of their state of differenti-
ation and responsiveness to re-stimulation are equally important
parameters to consider. Day 14 γδT cells bear surface markers
reminiscent of TEM cells, although the validity of adopting this
terminology for γδT cells is questionable. TEM cells and central-
memory T (TCM) cells describe subsets of memory αβT cells
present in peripheral blood and were originally defined on the basis
of the expression of lymph node-homing markers (CD62L, CCR7)
(54). Memory subsets, most notably CD8+ αβT cell subsets, were
further defined by the expression of CD45RA and CD45RO in
combination with co-stimulatory receptors (CD27, CD28) (55).
Except for CCR7/CD27/CD28 triple-negative CD8+ αβT cells, all
T cell subsets purely reflect a hallmark of αβT cell biology, namely
their need to interact with DC in lymph nodes or peripheral
tissues in order to receive appropriate activation/differentiation
signals. γδT cells, including the dominant subset of Vγ9Vδ2-
TCR+ γδT cells in peripheral blood, are not controlled by DC in
secondary lymphoid tissues, suggesting fundamental mechanistic
differences in controlling responsiveness between these two classes
of T cells. Nevertheless, day 14 γδT cells share hallmarks of late-
differentiated TEM cells with intact replication capacity because
they lack CD45RA, CCR7, and for the most part CD27 but largely
maintain CD28 expression. Uniform expression of KLRG1, other-
wise a marker for replication-defective CD8+ αβT cells (56), may
signify a role for these cells in epithelial tissues where the KLRG1
ligand, E-cadherin, is ubiquitously expressed (57). In agreement,
day 14 γδT cells responded well to re-stimulation with HMBPP
or zoledronate plus PBMC as assessed by cytokine production
and γδT cell proliferation. Of note, day 14 γδT cells primarily
produced pro-inflammatory cytokines (IFNγ, TNFα), much like
activated peripheral blood γδT cells (58) but failed to secrete reg-
ulatory cytokines TGFβ and IL-10 in response to HMBPP or to
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express the inhibitory receptors PD-1 and CTLA-4. Day 14 γδT
cells also maintained tumor cell-killing activity,most notably when
HMBPP-pre-treated tumor cells were used as target cells. Collec-
tively, stimulation of PBMC with zoledronate and culturing in the
presence of IL-2 plus IL-15 resulted in large numbers of func-
tionally competent γδT cells featuring immunostimulatory and
cytotoxic as opposed to inhibitory properties.
Most relevant for the potential use of expanded γδT cell as
a novel cellular vaccine were the abundant expression of APC-
relevant cell surface markers and the capacity of day 14 γδT cells
to trigger antigen-specific αβT cell responses in vitro. Professional
APC, such as DC, have to be able to initiate adhesive interac-
tions with αβT cells in order to allow αβT cells to screen the
APC surface for the presence of their cognate peptide–MHC com-
plexes (59). Engagement of αβTCR on CD8+ and CD4+ αβT cells
with peptide–MHC class I and class II complexes on DC, respec-
tively, leads to αβT cells priming and subsequent engagement of
co-stimulatory receptors initiates αβT cell proliferation and dif-
ferentiation. Interference in any of these early steps has profound
effects on αβT cell responses. We here show that day 14 γδT cells
abundantly express CD11a, CD54 (adhesion) and HLA-DR and
HLA-ABC (antigen-presentation) molecules as well as the CD28
ligands CD80 and CD86, which trigger essential CD28-mediated
co-stimulatory signals in αβT cells (60). Indeed, this APC phe-
notype is mirrored by the APC function, as demonstrated by the
induction of antigen-specific CD4+ and CD8+ αβT cell prolifer-
ation in response to expanded γδT cells that have processed either
the complex microbial antigen PPD or influenza M1 protein. We
did not notice significant differences between day 14 γδT cells
derived from PBMC of healthy individuals as compared to patients
with cancer with regard to their ability to cross-present M1 pro-
tein. Of note, the cellular composition of PBMC from melanoma
patients differed substantially from PBMC of healthy individuals,
possibly reflecting the history of cancer treatment regimens and
potential immunosuppressive conditions (61). However, day 14
γδT cells have undergone many rounds of cell division and, thus,
appear“far removed”from the inhibitory conditions present in the
original PBMC samples, which may explain their undiminished
functionality. In this respect, our data confirm previous find-
ings about γδT cell-induced CD8+ αβT cell responses although
patients-derived γδT cells were examined at their peak-time (day
7/8) of proliferation (25, 27).
In summary, we demonstrated that expanded γδT cells from
PBMC of both healthy individuals and patients with cancer dis-
played potent APC functions and responsiveness to γδT cell anti-
gens. Our data support the view that expanded γδT cells may be
exploited as a novel cellular vaccine for the treatment of patients
with cancer. Relatively small (≈100 ml) blood samples of patients
suffice to generate large numbers (>109) of expanded γδT cells
within 2 weeks of in vitro culture in response of zoledronate and
the T cell growth and survival factors IL-2 and IL-15. Cultured
γδT cells efficiently take up, process, and cross-present complex
antigens (20, 22), including proteins present in cell extracts (23).
Therefore, we propose to treat expandedγδT cells with tumor anti-
gens, either in the form of cellular extracts derived from patients’
own tumor cells or from heterologous tumor cell lines. The lat-
ter approach would also provide highly stimulatory alloantigens
that may boost the adaptive immune response. Tumor-antigen-
loaded γδT cells are then infused into patients. Since expanded
γδT cells retain the capacity to secrete pro-inflammatory cytokines
(IFNγ, TNFα) and to express, albeit at reduced levels, lymph
node-homing markers (CCR7, CD62L), the infusion of tumor-
antigen-loaded γδT cells may be followed by a single treatment
with zoledronate. Thus, a fraction of activated γδT cells may
acquire the ability to home to secondary lymphoid tissues (spleen,
lymph nodes), where mobilization of endogenous tumor-specific
αβT cells takes place. The anti-tumor activity mediated by this
new wave of endogenous effector T cells may be further supported
by the infused γδT cells that retained direct tumor cell-killing
activity. A substantial body of evidence by numerous laborato-
ries has already documented the safety of large (and repetitive)
infusions of γδT cells (33, 37, 38, 62–67). Now, we need to test
whether the clinical outcome is improved by treating patients
with tumor-antigen-presenting γδT cells targeting the patients’
own tumor-specific T cells as opposed to tumor cells. It is possi-
ble that the immune stimulatory effects of γδT cell-based vaccines
are further enhanced when applied in combination with promis-
ing immune checkpoint inhibitors (anti-PD-1 and anti-CTLA-4
antibodies) (68).
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